

Special Issue

Skin Cancers as a Paradigm Shift: From Pathobiology to Treatment

Message from the Guest Editors

It is well-established that in humans, compared to other body tissues and organs, most malignant and non-malignant neoplasms affect the skin and, in particular, the epidermis. Ultraviolet radiation (UVR) is an established complete carcinogen for the skin, responsible for >90% of all skin cancers and with a particular impact on epidermal cancers. Thus, human skin neoplasms, particularly UVR-induced keratinocyte skin cancers, are a suitable model for studying two key dogmas of contemporary oncology: Multifocal carcinogenesis within cutaneous cancerization fields and multistage carcinogenesis.

This Special Issue aims to: Update the current knowledge on the epidemiology and pathobiology of skin cancers;

Address recent developments in the non-invasive imaging-based approaches to the diagnosis, treatment evaluation, and follow-up of skin cancer, also incorporating novel advances from the field of artificial intelligence;

Investigate the potential of minimally invasive therapeutic modalities for treating selected types of skin neoplasms or addressing the specific treatment demands of certain patient populations

Guest Editors

Dr. Ioannis D. Bassukas

Dr. Panagiota Spyridonos

Dr. Georgios Gaitanis

Deadline for manuscript submissions

closed (30 August 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/139783

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)